- Home
- ALKS
ALKS
Alkermes plc
as of 12-15-2025 12:27pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 4.8B | IPO Year: | 1991 |
| Target Price: | $42.85 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.02 | EPS Growth: | 2.44 |
| 52 Week Low/High: | $25.16 - $36.45 | Next Earning Date: | 10-28-2025 |
| Revenue: | $1,521,338,000 | Revenue Growth: | 1.08% |
| Revenue Growth (this year): | -3.76% | Revenue Growth (next year): | 24.22% |
AI-Powered ALKS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alkermes plc (ALKS)
EVP R&D, Chief Medical Officer
Avg Cost/Share
$29.30
Shares
4,000
Total Value
$117,200.00
Owned After
65,740
SEC Form 4
EVP R&D, Chief Medical Officer
Avg Cost/Share
$30.38
Shares
9,000
Total Value
$273,441.60
Owned After
65,740
SEC Form 4
EVP R&D, Chief Medical Officer
Avg Cost/Share
$31.53
Shares
9,000
Total Value
$283,776.30
Owned After
65,740
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 1, 2025 | Sell | $29.30 | 4,000 | $117,200.00 | 65,740 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Nov 3, 2025 | Sell | $30.38 | 9,000 | $273,441.60 | 65,740 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Oct 15, 2025 | Sell | $31.53 | 9,000 | $283,776.30 | 65,740 |
Compare ALKS vs Leading Stocks
See how ALKS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.